1. Scrip
  2. >>Business
  3. >>Strategy

Altimmune Outlines Pemvidutide Plans In MASH And Beyond

 
• By Joseph Haas

The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.

Liver care
Altimmune will study its MASH candidate in alcohol-related liver disease • Source: Shutterstock

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the dual GLP-1/glucagon receptor agonist’s reach far beyond its most advanced indications of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Key Takeaways
  • Altimmune made a case for its dual GLP-1/glucagon receptor agonist pemvidutide in multiple diseases at an investor day, including MASH and obesity.

The company described the drug as Phase III-ready in obesity, soon to report Phase IIb histology data in MASH and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

More from Therapy Areas

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.